$50.33 −$0.08 (-0.16%)
休市 · Nov 7, 9:10 am ET · 最新盘后价 $50.33 0.00%
开盘$49.07
昨收$50.41
当日区间$48.94 – $50.74
成交量3.19M
市值$100.88B
市盈率（TTM）17.5
股息率3.56%
GSK 相关新闻
匹配 GlaxoSmithKline 或代码 GSK 的头条新闻，按最新排序。
- Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
- GSK Target Started at GBP19.75 by RBC
- US Stock Market Movements | HUTCHMED (HCM.US) Surges Over 14% on Licensing Agreement with GlaxoSmithKline for Cancer Drug 正面
- GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.
- GSK Target Raised to GBP22.00 From GBP20.00 by Berenberg 正面
- J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
- J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
- J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
- TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $70
- TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70 正面
- J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
- GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
- Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $67.1 正面
- TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Raises Target Price to $70 正面
- J.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)
暂无评论——快来第一个聊聊 GSK。
登录后参与讨论。